相关实验视频

Updated: Jul 15, 2026

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

染色体21的剂量对抗病毒基因的诱导能力的影响

U H Tan

    Nature
    |January 24, 1975
    PubMed
    概括

    No abstract available in PubMed .

    更多相关视频

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
    15:49

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

    Published on: June 9, 2022

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
    08:32

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

    Published on: May 23, 2025

    相关实验视频

    Last Updated: Jul 15, 2026

    Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
    08:42

    Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

    Published on: January 15, 2018

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
    15:49

    Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

    Published on: June 9, 2022

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
    08:32

    Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

    Published on: May 23, 2025

    相关概念视频

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    JoVE
    关于 JoVE
    概览领导团队博客JoVE 帮助中心
    作者
    出版流程编辑委员会范围与政策同行评审常见问题投稿
    图书馆员
    用户评价订阅访问资源图书馆顾问委员会常见问题
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
    使用条款与条件
    隐私政策
    政策
    Jove
    Visualize
    联系我们